Market Exclusive

Analyst Activity – Cantor Fitzgerald Reiterates Buy on Array BioPharma (NASDAQ:ARRY)

Analyst Ratings For Array BioPharma (NASDAQ:ARRY)

Today, Cantor Fitzgerald reiterated its Buy rating on Array BioPharma (NASDAQ:ARRY) with a price target of $13.00.

There are 1 hold rating, 6 buy ratings on the stock.

The current consensus rating on Array BioPharma (NASDAQ:ARRY) is Buy (Score: 2.86) with a consensus target price of $11.86 per share, a potential 39.33% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Array BioPharma (NASDAQ:ARRY)
Array BioPharma (NASDAQ:ARRY) has insider ownership of 2.60% and institutional ownership of 97.88%.

Recent Trading Activity for Array BioPharma (NASDAQ:ARRY)
Shares of Array BioPharma closed the previous trading session at 8.56 up +0.05 0.59% with 1,305,343 shares trading hands.

Exit mobile version